Tenofovir: FDA hearing October 3, public comment deadlines September 26.
James
J S
JS
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010349:Patient Compliance; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000068698:Tenofovir; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000225:Adenine